Senate Finance Committee releases text of bill to lower drug prices

Senate Finance Committee leaders yesterday released the statutory text for the Prescription Drug Pricing Reduction Act of 2019 (S-2543), which closely mirrors the chairman’s mark that passed the committee in July.
Among other provisions, the bill would:
- Make a number of changes to the Medicare Part D program, including reducing beneficiary cost-sharing and tying drug price increases to the rate of inflation.
- Make more information on pharmacy benefit manager practices and manufacturer drug pricing publicly available.
- Change how Medicare calculates Part B prescription drug payment amounts to lower spending and beneficiary out-of-pocket costs; apply "site-neutral" payment cuts to drug administration services furnished in grandfathered off-campus provider-based departments; and cap at $1,000 the add-on payment for each Part B drug paid under the average sales price or wholesale acquisition cost methodology.
- Allow Medicaid to pay for gene therapies for rare disease through new risk-sharing value-based agreements; pressure manufacturers to lower list prices and report more accurate calculations of their rebate obligations; and prevent spread pricing by PBMs in the Medicaid program.
- Increase the Medicaid rebate cap from 100% to 125% of a drug's average manufacturing price, intended to discourage drug manufacturers' price increases in non-Medicaid markets; and allow states to apply Medicaid drug rebate requirements to drugs provided in outpatient hospital services through bundled or value-based payment arrangements.
Related News Articles
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Chairperson's File
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…